Physician profile
Robert Nicholas Mitro
NPI 1184685786
$1,056.49
in general payments reported to CMS, 2019-2025
12 companies · $21.21 in 2025
The $21.21 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $121 · 2021: $50.96 · 2022: $12.14 · 2024: $41.09 · 2025: $21.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.69 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.69 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $202.19 | 2019-2024 | Vafseo |
| Alexion Pharmaceuticals, INC. | $191.85 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $183.27 | 2019 | |
| Vifor Pharma, INC. | $142.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $123.14 | 2019-2020 | |
| Amgen INC. | $54.21 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $37.91 | 2019 | |
| Eisai INC. | $37.69 | 2024-2025 | |
| Shire North American Group INC | $33.35 | 2019 | |
| Opko Pharmaceuticals, LLC | $26.62 | 2019 | |
| Baxter Healthcare | $12.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mitro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.